Chinese Journal of Cancer Biotherapy, Volume. 32, Issue 7, 716(2025)
Mechanism of bexarotene in suppressing double hit lymphoma via modulation of the c-Myc pathway: Insights from WGCNA
[3] [3] DLOUHY I, KARUBE K, ENJUANES A,et al. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma[J]. Br J Haematol, 2022, 196(3): 589-598. DOI:10.1111/bjh.17858.
[4] [4] RIEDELL P A, SMITH S M. Double hit and double expressors in lymphoma: Definition and treatment[J]. Cancer, 2018, 124(24):4622-4632. DOI:10.1002/cncr.31646.
[5] [5] ZHANG J C, ZHOU S, JIANG S S,et al. Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase[J/OL]. J Cancer Res Clin Oncol,2024, 150(9): 426[2024-10-01]. https://pmc.ncbi.nlm.nih.gov/articles/PMC11413099/. DOI:10.1007/s00432-024-05939-4.
[7] [7] ROUANET J, JOULIE I, LAMBERT C,et al. Real-life use of bexarotene for T-cell cutaneous lymphoma management: efficacy and tolerance with low doses[J/OL]. Acta Derm Venereol, 2022,102: adv00746[2024-10-01]. https://pubmed.ncbi.nlm.nih.gov/35312021/. DOI:10.2340/actadv.v102.718.
[8] [8] HACIOGLU C, KAR F, KACAR S,et al. Bexarotene inhibits cell proliferation by inducing oxidative stress, DNA damage and apoptosisviaPPAR/NF-B signaling pathway in C6 glioma cells. [J/OL]. Med Oncol, 2021, 38(3): 31[2024-10-01]. https://link.springer.com/article/10.1007/s121032-021-01476-z. DOI:10.1007/s12032-021-01476-z.
[9] [9] LANGFELDER P, HORVATH S. WGCNA: an R package for weighted correlation network analysis[J/OL]. BMC Bioinformatics, 2008, 9: 559[2024-10-01]. https://pubmed.ncbi.nlm.nih.gov/19114008/. DOI:10.1186/1471-2105-9-559.
[10] [10] AUKEMA S M, KREUZ M, KOHLER C W,et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma[J]. Haematologica,2014, 99(4): 726-735. DOI:10.3324/haematol.2013.091827.
[11] [11] WONG S F. Oral bexarotene in the treatment of cutaneous T-cell lymphoma[J]. Ann Pharmacother, 2001, 35(9): 1056-1065. DOI:10.1177/106002800103500903.
[12] [12] TANITA K, FUJIMURA T, SATO Y,et al. Bexarotene reduces production of CCL22 from tumor-associated macrophages in cutaneous T-cell lymphoma[J/OL]. Front Oncol, 2019, 9: 907[2024-10-01]. https://doi.org/10.3389/fonc.2019.00907. DOI:10.3389/fonc.2019.00907.
[13] [13] WU K, ZHANG Y, XU X C,et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice[J]. Cancer Res, 2002,62(22): 6376-6380.
[14] [14] WANG J, LIANG Y, MENG Y,et al. Assessment of lncRNA biomarkers based on NETs for prognosis and therapeutic response in ovarian cancer[J/OL]. Sci Rep, 2025, 15(1): 13042[2024-06-11]. https://pmc.ncbi.nlm.nih.gov/articles/PMC12000398/. DOI:10.1038/s41598-025-97548-5.
[15] [15] AI X H, MAO F, SHEN S P,et al. Bexarotene inhibits the viability of non-small cell lung cancer cellsviaslc10a2/PPAR/PTEN/mTOR signaling pathway[J/OL]. BMC Cancer, 2018, 18(1): 407[2024-10-01]. http://dx.doi.org/10.1186/s12885-018-4224-x. DOI:10.1186/s12885-018-4224-x.
[16] [16] KOBAYASHI T, MITSUHASHI A, PIAO H Y,et al. Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis[J/OL]. Sci Rep, 2022, 12(1):11123[2024-10-01]. https://pubmed.ncbi.nlm.nih.gov/35778597/. DOI:10.1038/s41598-022-15348-7.
[17] [17] SONG Y P, GAO F, PENG Y,et al. Long non-coding RNA DBH-AS1 promotes cancer progression in diffuse large B-cell lymphoma by targeting FN1viaRNA-binding protein BUD13[J]. Cell Biol Int,2020, 44(6): 1331-1340. DOI:10.1002/cbin.11327.
[18] [18] RAEESZADEH-SARMAZDEH M, DO L D, HRITZ B G. Metalloproteinases and their inhibitors: potential for the development of new therapeutics[J/OL]. Cells, 2020, 9(5): 1313[2024-10-01]. https://pubmed.ncbi.nlm.nih.gov/32466129/. DOI:10.3390/cells9051313.
[20] [20] HUANG J C, ZHANG L L, WAN D L,et al. Extracellular matrix and its therapeutic potential for cancer treatment[J/OL]. Signal Transduct Target Ther, 2021, 6(1): 153[2024-10-01]. https://pubmed.ncbi.nlm.nih.gov/33888679/. DOI:10.1038/s41392-021-00544-0.
[21] [21] NAJAFI M, FARHOOD B, MORTEZAEE K. Extracellular matrix(ECM) stiffness and degradation as cancer drivers[J]. J Cell Biochem, 2019, 120(3): 2782-2790. DOI:10.1002/jcb.27681.
[22] [22] NEILL T, SCHAEFER L, IOZZO R V. Decorin: a guardian from the matrix[J]. Am J Pathol, 2012, 181(2): 380-387. DOI:10.1016/j.ajpath.2012.04.029.
[24] [24] ZHAO S F, YIN X J, ZHAO W J,et al. Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers[J]. Oncol Lett, 2020, 19(3): 1673-1682. DOI:10.3892/ol.2020.11266.
[25] [25] MAHDIZADEHI M, SAGHAEIAN JAZI M, MIR S M,et al. Role of fibrilins in human cancer: a narrative review[J/OL]. Health Sci Rep, 2023, 6(7): e1434[2024-10-01]. https://pubmed.ncbi.nlm.nih.gov/37469709/. DOI:10.1002/hsr2.1434.
[26] [26] ZANG Y Q, DONG Q P, LU Y,et al. Lumican inhibits immune escape and carcinogenic pathways in colorectal adenocarcinoma[J]. Aging, 2021, 13(3): 4388-4408. DOI:10.18632/aging.202401.
Get Citation
Copy Citation Text
HE Tiantian, LI Hongyi, GENG Jie, HOU Chuandong, ZHANG Hong, ZHANG Hui, ZHAO Peng, LU Xuechun, HE Peifeng. Mechanism of bexarotene in suppressing double hit lymphoma via modulation of the c-Myc pathway: Insights from WGCNA[J]. Chinese Journal of Cancer Biotherapy, 2025, 32(7): 716
Category:
Received: Oct. 23, 2024
Accepted: Aug. 26, 2025
Published Online: Aug. 26, 2025
The Author Email:
